OPK insider trading
NasdaqGS HealthcareOPKO HEALTH, INC.: insider trade history from SEC Form 4 filings.
About OPKO HEALTH, INC.
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins or peptides; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products for a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. OPKO Health, Inc. was founded in 2007 and is headquartered in Miami, Florida.
Company website: www.opko.com
OPK insider activity at a glance
FilingIQ tracks 5,293 insider transactions for OPK in filings since Jan 2, 2015. The most recent transaction is dated Jul 24, 2026.
Across the full history, 5,152 open-market purchases
and 11 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on OPK insider trades is 44.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest OPK Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Politicians who have traded OPK
Frequently asked
- How many insider trades does FilingIQ track for OPK?
- FilingIQ tracks 5,293 Form 4 insider transactions for OPK (OPKO HEALTH, INC.), covering filings from Jan 2, 2015 onwards. 2 of those are dated within the last 90 days.
- Are OPK insiders net buyers or net sellers?
- Across the full Form 4 history for OPK, 5,152 transactions (97%) were open-market purchases and 11 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does OPK insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is OPK in?
- OPKO HEALTH, INC. (OPK) is classified in the Healthcare sector, specifically Diagnostics & Research, with a current market capitalisation of $911.66M.
Methodology & sources
Every OPK insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.